Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

JUNE 16, 2016

Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Waltham, MA — Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.

“The studies outlined below add to the evidence reflected in our now over 50 studies of the significant impact our advanced decision support capabilities have on the quality and cost of diabetes care, both in and out of the hospital,” said Glytec’s Chief Medical Officer, Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC. “We continue to work closely with the diabetes community in creating solutions that generate meaningful and scalable results. Our great thanks to the clinicians and colleagues who led the research efforts across numerous health systems and, of course, to the ADA for providing the opportunity to present the insights and evidence.”

The following abstracts were presented:

  • Glucommander Outpatient, A Cloud-based Insulin Management Solution Adjusted Insulin Doses and Achieved 2.7% Drop In A1c Percentage Points
    The study evaluated the effectiveness of Glucommander outside the hospital for 41 patients who were previously treated with standard of care methods. Results found that the Glucommander worked well for all patients, including Type 1, Type 2, and even complex cases. Patients managed with the insulin dosing decision support system experienced an average reduction in A1c of 2.7% over a three month period. A handful of patients have continued on Glucommander for six and nine months, and maintained the 2.7% A1c reduction. This cloud-based decision support solution also resulted in an average of 6.1 days to target, zero severe hypoglycemic episodes and a 96% patient satisfaction rating.
    Presented by: Dr. Bruce Bode, Atlanta Diabetes Associates
  • A Comparison of Glycemic Outcomes for Two Computerized Insulin Infusion Algorithms in CV Surgery Patients
    This study, which compared the safety and efficacy of Glucommander and EndoTool (ET), found that Glucommander was more clinically effective and safer than ET for cardiovascular (CV) surgery patients. Hyperglycemia blood glucose (BG) > 180 mg/dL was significantly reduced with Glucommander compared with ET 6% vs. 3.9% (p=< 0.00001). There were no severe hypoglycemia < 40 mg/dL events with Glucommander and there was a significant decrease of 58% in hypoglycemia < 70 mg/dL with Glucommander compared with ET. Nursing time from BG due to IV insulin titration was reduced by 47% with Glucommander compared with ET.
    Presented by: Dr. Valerie Garrett, Medical Director for the Diabetes Center at Mission Hospital
  • Sepsis-Related Dysglycemia: Can a Computerized IV Insulin Algorithm Improve Glycemic Control, Reduce Hypo and Reduce 30-Day Readmissions?
    This study compared whether Glucommander or traditional IV protocols (NonGM) achieved target BG with less mild and severe hypoglycemia. The results found that patients treated with IV insulin utilizing Glucommander had a higher percentage of BG in target range in combination with lower hypoglycemia rates (< 70 mg/dL 0.51% vs. 1.88% and < 40 mg/dL 0.0% vs. 0.3% with Glucommander vs. NonGM, respectively). Readmissions were very low in both groups with GM having zero patients and NonGM having five.
    Presented by: Robby Booth, Senior Vice President, R&D, Glytec, and Dr. Andrew Rhinehart, Chief Medical Officer, Glytec
  • The Frequency of Hypoglycemia in Hospitalized Patients Treated with Insulin Increases Overall Costs Associated with Hospitalization and Length of Stay
    This study examined the association between inpatient hypoglycemia and increased costs of care. As a group, patients with a severe hypoglycemic episode had increased length of stay (LOS) (12.3 vs. 4.3 days) and higher overall costs ($104,713 vs. $29,700) compared to patients with diabetes treated with insulin without severe hypoglycemia. Frequency of hypoglycemia was also associated with increasing costs and LOS such that more than three episodes of severe hypoglycemia increased LOS an additional four days (14.4 days) and increased associated costs for the admission an additional $94,948.
    Presented by: Dr. Jagdeesh Ullal, Professor of Medicine, Division of Endocrinology Eastern Virginia Medical School
  • Selecting the Initial Multiplier and Target Glucose of a Computer-guided Algorithm (Glucommander) during Treatment of Diabetic Ketoacidosis
    The results of this study unveiled the optimal treatment parameters for Glucommander. The results of this study indicate that a conservative initial multiplier of 0.01 and a BG target of 120-180 mg/dL with Glucommander are safe and effective in treating patients with diabetic ketoacidosis (DKA) when compared to other multipliers or tighter BG targets. The study suggests that an automated approach was effective at treating patients with DKA with a low incidence of hypoglycemia and a quick time to resolution of DKA.
    Presented by: Dr. Guillermo Umpierrez, Professor of Medicine, Division of Endocrinology, Emory University School of Medicine

About Glytec

Founded in 2006, Glytec is a rapidly growing digital health company specializing in integrated inpatient and outpatient technologies for diabetes care, with the mission of improving medication management and glycemic control across the continuum. eGMS®, Glytec’s cloud-based glycemic management decision support system, enables providers, payers, and patients to significantly reduce the frequency, risks, and costs of hyperglycemia and hypoglycemia. The modular eGMS centers on the Glucommander suite of FDA-cleared, complex proprietary dosing algorithms for IV, subcutaneous, and pediatric insulin dosing. The management of patients requiring insulin therapy is furthered by seamless electronic health record and connected device integration (SmartClick), robust analytics (GlucoMetrics), and surveillance (GlucoSurveillance) capabilities. eGMS interventional clinical decision support tools allow providers to standardize processes and personalize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit

View on Business Wire